In a nutshell This article investigated the safety and effectiveness of androgen-deprivation therapy (ADT) combined with external beam radiation therapy (EBRT) for the treatment of locally advanced prostate cancer (LAPC). The authors concluded that ADT combined with EBRT is a safe and effective treatment option for these...
Read MoreIn a nutshell This article investigated the safety and effectiveness of docetaxel (Taxotere)-based chemotherapy in combination with dexamethasone (Decadron) for the treatment of castration-resistant prostate cancer (CRPC). The authors concluded that this treatment combination is a safe and effective treatment option for...
Read MoreIn a nutshell This phase 1/2 trial will investigate BMS-986253, an experimental drug, in combination with nivolumab (Opdivo) to treat advanced cancer. The main outcomes will be the occurrence of side effects and tumor response. The details Advanced cancers have limited treatment options. New drugs are in development to improve patient prognosis. These...
Read More
In a nutshell This article investigated the safety and effectiveness of Lutetium-177 PSMA (LuPSMA) for the treatment of metastatic castration-resistant prostate cancer (mCRPC). The authors concluded that LuPSMA is a safe and effective treatment option for these patients. Some background mCRPC is cancer which has spread from its original site...
Read MoreIn a nutshell This phase 2 trial is examining the effectiveness and safety of sacituzumab govitecan (IMMU-132) in patients with metastatic castration-resistant prostate cancer (mCRPC) who are having cancer progression on abiraterone (Zytiga) or enzalutamide (Xtandi). The main outcome to be measured will be the PSA (a...
Read MoreIn a nutshell This phase 3 trial is examining the effectiveness and safety of low dose rate (LDR) vs high dose rate (HDR) prostate brachytherapy (BT) for patients with prostate cancer (PC). The main outcome to be measured will be the quality of life in terms of urinary symptoms. This trial is recruiting in British Columbia,...
Read MoreIn a nutshell This phase 3 trial is examining the effectiveness and safety of niraparib (Zejula) in combination with abiraterone acetate (Zytiga) and prednisone (Deltasone) vs abiraterone acetate and prednisone plus placebo for patients with metastatic prostate cancer. The main outcome to be measured will be the survival...
Read More
In a nutshell This study reviewed the role of external beam radiation therapy in the treatment of prostate cancer. Some background Prostate cancer (PC) is a common and treatable cancer in men. There are many treatment options available. Treatment is usually chosen based on the risk of the cancer progressing, and patient...
Read More
In a nutshell This phase 2 trial will investigate the safety and effectiveness of stereotactic body radiation therapy (SBRT) in patients with localized prostate cancer (PC) who had surgical removal of the prostate. The main outcomes will be survival without recurrence and side effects. This study is recruiting in Los Angeles, California, the...
Read More
In a nutshell This study examined the biochemical recurrence (BCR) of prostate cancer after minimally invasive prostate surgery. This study concluded the risk of BCR of prostate cancer decreases as the number of years after surgery without the disease increases. Some background One treatment option for patients with prostate...
Read More
In a nutshell This study investigated if abiraterone acetate (Zytiga) and prednisone (Deltasone) added to androgen deprivation therapy (ADT) improve survival in patients with advanced prostate cancer. They found that this combination was effective at improving survival in these patients. Some background...
Read More
In a nutshell This phase 2 trial will investigate the safety and effectiveness of nivolumab (Opdivo) in recurrent prostate cancer (PC). The main outcome will be disease control. This trial is recruiting at two locations in Boston, MA, US. The details Prostate cancer (PC) is a highly treatable cancer in men. Patients are usually...
Read More
